Neuroendocrine tumors affect about 35 out of every 100,000 people globally, whereas the incidence is thought to affect about 6 out of every 100,000 people annually. There has been an increase in the number of cases in the United States with more than six times the growth between 1973 and 2012, mainly because of increased awareness about the disease and better diagnostic facilities. Several companies are engaged in research initiatives which are boosting the drug landscape significantly.
The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing neuroendocrine tumors pipeline development activities.
Upon the detection of tumor, surgery is considered the first line of neuroendocrine tumors treatment to remove the entire tumor. Targeted drugs, such as everolimus and somatostatin analogs are preferred for advanced or metastatic NETs. These therapies help manage the symptoms and decrease the growth of the tumor. Radiation therapy is often used to subside symptoms in incurable tumors, while chemotherapy is often used to treat aggressive malignancies. For some types of advanced NETs, peptide receptor radionuclide treatment (PRRT) proves to be beneficial. For instance, a trial is investigating the tolerability and efficacy of a drug that could be used in unresectable and locally advanced cancer. The presence of a large number of clinical trials for neuroendocrine tumors has influenced the pipeline landscape positively.
This product will be delivered within 3-5 business days.
Report Coverage
The Neuroendocrine Tumors Drug Pipeline Report by the publisher gives comprehensive insights into neuroendocrine tumors drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neuroendocrine tumors. The report includes the analysis of over 50 pipeline drugs and 15+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from neuroendocrine tumors.The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing neuroendocrine tumors pipeline development activities.
Neuroendocrine Tumors Drug Pipeline Outlook
Neuroendocrine cells combine the properties of nerve cells and hormone-producing endocrine cells. Neuroendocrine tumors occur due to uncontrolled cell growth which may be because of genetic mutations. Although NETs can occur anywhere in the body, the pancreas, gastrointestinal system, and the lungs are where they most frequently do. There is a correlation between an elevated risk of developing a certain type of NETs and certain inherited genetic disorders, such as multiple endocrine neoplasia type 1 (MEN1).Upon the detection of tumor, surgery is considered the first line of neuroendocrine tumors treatment to remove the entire tumor. Targeted drugs, such as everolimus and somatostatin analogs are preferred for advanced or metastatic NETs. These therapies help manage the symptoms and decrease the growth of the tumor. Radiation therapy is often used to subside symptoms in incurable tumors, while chemotherapy is often used to treat aggressive malignancies. For some types of advanced NETs, peptide receptor radionuclide treatment (PRRT) proves to be beneficial. For instance, a trial is investigating the tolerability and efficacy of a drug that could be used in unresectable and locally advanced cancer. The presence of a large number of clinical trials for neuroendocrine tumors has influenced the pipeline landscape positively.
Neuroendocrine Tumors - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of neuroendocrine tumor drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 20+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Molecule Type
The neuroendocrine tumors therapeutic assessment report covers 20+ drug analyses based on molecule type:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptides
- Polymer
- Gene Therapy
By Route of Administration
The pipeline assessment report covers 20+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Neuroendocrine Tumors - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for neuroendocrine tumors with around 18 pipeline drugs in phase II.Neuroendocrine Tumors Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under neuroendocrine tumors pipeline analysis includes recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Stud ies that targeted monoclonal antibodies have been highly effective in the management of neuroendocrine tumors. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for neuroendocrine tumors.Neuroendocrine Tumors Clinical Trials Assessment - Competitive Dynamics
The report for the neuroendocrine tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in neuroendocrine tumors clinical trials:- Novartis Pharmaceuticals
- Provectus Biopharmaceuticals, Inc.
- Hutchmed (China) Ltd
- Camurus AB
- Wren Laboratories LLC
- TaiRx, Inc.
- ITM Solucin GmbH
- Ipsen SA
- Radiomedix, Inc.
- Sinotau Pharmaceutical Group
- Clarity Pharmaceuticals Ltd
Neuroendocrine Tumors - Pipeline Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for neuroendocrine tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of neuroendocrine tumors drug candidates.Drug: Lutetium Oxodotreotide
The trial compares Lutetium [177Lu] Oxodotreotide Injection to high-dose Octreotide LAR in treating advanced gastroenteropancreatic neuroendocrine tumors. The trial is sponsored by Sinotau Pharmaceutical Group and is currently under phase III.Drug: Lutetium Edotreotide
The study evaluates 177Lu-Edotreotide PRRT versus Everolimus in treating inoperable, progressive gastroenteric or pancreatic neuroendocrine tumors. The trial is sponsored by ITM Solucin GmbH and is currently under phase III.Drug: Surufatinib
The trial evaluates the efficacy and tolerability of neuroendocrine tumors drug candidate Surufatinib in Japanese patients. The trial is sponsored by Hutchmed and is currently under phase II.Reasons To Buy This Report
The Neuroendocrine Tumors Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neuroendocrine tumors collaborations, regulatory environments, and potential growth opportunities within neuroendocrine tumors pipeline insights.Key Questions Answered in the Neuroendocrine Tumors - Pipeline Assessment Report
- Which companies/institutions are leading the neuroendocrine tumors drug development?
- What is the efficacy and safety profile of neuroendocrine tumors pipeline drugs?
- Which company is leading the neuroendocrine tumors pipeline development activities?
- What is the current neuroendocrine tumors commercial assessment?
- What are the opportunities and challenges present in the neuroendocrine tumors drug pipeline landscape?
- What is the efficacy and safety profile of neuroendocrine tumors pipeline drugs?
- Which company is conducting major trials for neuroendocrine tumors drugs?
- Which companies/institutions are involved in neuroendocrine tumors collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in neuroendocrine tumors?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Neuroendocrine Tumors Pipeline
4 Patient Profile: Neuroendocrine Tumors Pipeline
5 Neuroendocrine Tumors Pipeline: Epidemiology Snapshot
6 Neuroendocrine Tumors Pipeline: Market Dynamics
7 Neuroendocrine Tumors Pipeline: Key Facts Covered
8 Neuroendocrine Tumors Pipeline, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Neuroendocrine Tumors Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Neuroendocrine Tumors Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Neuroendocrine Tumors Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Neuroendocrine Tumors Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Neuroendocrine Tumors, Key Drug Pipeline Companies
